Neuphoria Therapeutics (NASDAQ:NEUP) Upgraded at Zacks Research

Zacks Research upgraded shares of Neuphoria Therapeutics (NASDAQ:NEUP) from a strong sell rating to a hold rating in a research note published on Tuesday,Zacks.com reports.

Several other research firms also recently weighed in on NEUP. Weiss Ratings restated a “sell (d-)” rating on shares of Neuphoria Therapeutics in a research report on Thursday, January 22nd. HC Wainwright reduced their price objective on Neuphoria Therapeutics from $21.00 to $7.00 and set a “buy” rating for the company in a research note on Friday, December 5th. Finally, Wall Street Zen lowered Neuphoria Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, November 23rd. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $21.00.

Neuphoria Therapeutics Stock Down 0.2%

Shares of NASDAQ NEUP opened at $3.99 on Tuesday. The firm has a market cap of $21.47 million, a price-to-earnings ratio of -0.82 and a beta of 0.52. The company’s 50-day simple moving average is $4.04 and its 200-day simple moving average is $7.48. Neuphoria Therapeutics has a 52-week low of $3.64 and a 52-week high of $21.40.

Neuphoria Therapeutics (NASDAQ:NEUP) last released its quarterly earnings results on Friday, November 14th. The company reported ($4.41) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($3.86). Equities research analysts anticipate that Neuphoria Therapeutics will post -1.56 EPS for the current fiscal year.

Hedge Funds Weigh In On Neuphoria Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Persistent Asset Partners Ltd purchased a new stake in Neuphoria Therapeutics in the 3rd quarter valued at $58,000. Millennium Management LLC purchased a new position in shares of Neuphoria Therapeutics during the 3rd quarter worth $216,000. Finally, FNY Investment Advisers LLC acquired a new position in shares of Neuphoria Therapeutics during the 4th quarter valued at about $102,000. Hedge funds and other institutional investors own 15.90% of the company’s stock.

About Neuphoria Therapeutics

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.